Cancer Immunology Immunotherapy,
Год журнала:
2024,
Номер
73(8)
Опубликована: Июнь 4, 2024
Abstract
Immunotherapy
is
one
of
the
most
promising
anti-cancer
treatment.
It
involves
activating
host's
own
immune
system
to
eliminate
cancer
cells.
Activation
cGAS-STING
pathway
therapeutic
approach
for
immunotherapy.
However,
in
human
clinical
trials,
targeting
results
insufficient
or
unsustainable
anti-tumor
response.
To
enhance
its
effectiveness,
combination
with
other
therapies
seems
essential
achieve
synergistic
systemic
The
aim
this
study
was
evaluate
whether
STING
agonist-cGAMP
anti-vascular
RGD-(KLAKLAK)
2
peptide
a
better
response
poorly
immunogenic
tumors
various
protein
and
α
v
β
3
integrin
status.
Combination
therapy
inhibited
growth
murine
breast
carcinoma
more
effectively
than
melanoma.
In
melanoma,
administration
agonist
alone
sufficient
obtain
satisfactory
effect.
both
tumor
models
we
have
noted
stimulation
innate
following
cGAMP
combination.
largest
population
cells
infiltrating
TME
after
were
activated
NK
Increased
infiltration
cytotoxic
CD8
+
T
lymphocytes
within
only
observed
melanoma
tumors.
they
also
expressed
“exhaustion”
PD-1
receptor.
contrast,
each
caused
drop
number
obtained
indicate
an
additional
benefit
from
combining
agent.
effect
depends
on
type
tumor,
status
microenvironment
expression
specific
proteins
such
as
family
integrin.
Cancers,
Год журнала:
2024,
Номер
16(6), С. 1205 - 1205
Опубликована: Март 19, 2024
Salivary
gland
cancer
(SGC)
is
rare
and
comprises
over
20
histological
subtypes.
Recently,
clinical
experience
regarding
immunotherapies
for
SGCs
has
been
accumulating,
yet
their
efficacy
remains
controversial.
Understanding
the
tumor
microenvironment
(TME),
including
expression
of
immune
checkpoint
molecules
in
SGC,
crucial
to
optimizing
immunotherapy.
In
this
review,
we
demonstrate
that
high-grade
mucoepidermoid
carcinoma
salivary
duct
generally
exhibit
immune-hot
TME
with
high
cell
infiltration,
frequent
genetic
mutations,
robust
molecule
expression.
contrast,
adenoid
cystic
carcinomas
an
immune-cold
TME.
While
reported
inhibitors
(ICIs)
poor,
several
studies
showed
promising
ICIs,
objective
response
rate
ranging
from
20.0–33.3%,
indicating
ICIs
might
be
beneficial
a
specific
population
SGC.
Molecule-targeted
therapies
anti-human
epidermal
growth
factor
receptor
2
anti-androgen
have
shown
against
Recent
evidence
indicates
these
could
targets
antigen-specific
chimeric
antigen
receptor-T
therapy
vaccines.
This
review
discusses
current
understanding
future
directions
SGCs,
ongoing
trials.
Cancers,
Год журнала:
2024,
Номер
16(7), С. 1245 - 1245
Опубликована: Март 22, 2024
A
retrospective
(N
=
140)
and
a
prospective
102)
observational
Israeli
study
by
Bar-Sela
colleagues
about
cannabis
potentially
adversely
impacting
the
response
to
immunotherapy
have
together
been
cited
202
times,
including
clinical
practice
guidelines.
There
also
concerns
on
PubPeer
outlining
irregularities
unverifiable
information
in
their
statistics
numerous
errors
calculating
percentages.
This
reanalysis
attempted
verify
data
analysis
while
non-parametric
statistics.
The
corrected
report
contained
22
Current Research in Biotechnology,
Год журнала:
2024,
Номер
7, С. 100210 - 100210
Опубликована: Янв. 1, 2024
Cancer
incidence
and
mortality
are
increasing
globally.
immunotherapies,
such
as
immune
checkpoint
inhibitors
adoptive
cell
therapy,
have
been
recognized
a
revolutionary
treatment
approach
to
combat
cancer.
However,
immunotherapeutic
resistance
cancer
recurrence
after
immunotherapy
alarm
us
further
explore
the
underlying
mechanisms
develop
new
immunotherapies.
Experimental
models
hold
great
value
in
research
studies
deciphering
mechanism
of
tumor
initiation
growth,
drug
discovery,
evaluation
efficacy.
The
ideal
model
is
expected
recapitulate
mimic
human
microenvironment,
including
biological,
physiological,
immunologic
functionality.
each
has
its
pros
cons,
selection
depends
on
many
factors,
features,
study
aims,
availability
related
resources.
In
this
review,
we
discussed
commonly
used
currently
immunotherapy,
2D
3D
vitro
culture
spheroid,
organoid,
hydrogel
model,
microfluidic
chip,
vivo
mouse
genetically
engineered
models,
chemically
induced
cell-derived
xenograft
(CDX)
patient-derived
(PDX)
humanized
models.
Both
preclinical
powerful
tools
for
studying
but
all
these
their
limitations.
To
promote
success
clinical
advanced
systems
that
can
better
environment
host
response
preferable
options
study.
Cancer Immunology Immunotherapy,
Год журнала:
2024,
Номер
73(8)
Опубликована: Июнь 4, 2024
Abstract
Immunotherapy
is
one
of
the
most
promising
anti-cancer
treatment.
It
involves
activating
host's
own
immune
system
to
eliminate
cancer
cells.
Activation
cGAS-STING
pathway
therapeutic
approach
for
immunotherapy.
However,
in
human
clinical
trials,
targeting
results
insufficient
or
unsustainable
anti-tumor
response.
To
enhance
its
effectiveness,
combination
with
other
therapies
seems
essential
achieve
synergistic
systemic
The
aim
this
study
was
evaluate
whether
STING
agonist-cGAMP
anti-vascular
RGD-(KLAKLAK)
2
peptide
a
better
response
poorly
immunogenic
tumors
various
protein
and
α
v
β
3
integrin
status.
Combination
therapy
inhibited
growth
murine
breast
carcinoma
more
effectively
than
melanoma.
In
melanoma,
administration
agonist
alone
sufficient
obtain
satisfactory
effect.
both
tumor
models
we
have
noted
stimulation
innate
following
cGAMP
combination.
largest
population
cells
infiltrating
TME
after
were
activated
NK
Increased
infiltration
cytotoxic
CD8
+
T
lymphocytes
within
only
observed
melanoma
tumors.
they
also
expressed
“exhaustion”
PD-1
receptor.
contrast,
each
caused
drop
number
obtained
indicate
an
additional
benefit
from
combining
agent.
effect
depends
on
type
tumor,
status
microenvironment
expression
specific
proteins
such
as
family
integrin.
